Asset Intelligence / Hyperliquid Context
Eli Lilly and Company / LLY
Archive-backed market intelligence for LLY: every HIPERWIRE mover article tied to this asset, plus a client-refreshed live market panel.
LLY tracks the value of 1 share of common stock in Eli Lilly and Company. Eli Lilly develops and manufactures pharmaceuticals, including treatments for diabetes, oncology, immunology, and other therapeutic areas.
Live Structure
Market Status
Loading current market structure…
- Builderxyz
- Categorystock
- Tracked Marketxyz:LLY
- Latest TweetOpen
No other live markets from this builder in the current screener.
No same-category alternatives are live in the current screener snapshot.
Archive Summary
Latest Archived Thesis
Eli Lilly Hits a Record High as Retatrutide's Phase 3 Data Lands at the ADA
LLY pushed to an all-time high near $1,226, up almost 11% in 24 hours, after Eli Lilly unveiled pivotal Phase 3 results for retatrutide at the American Diabetes Association's 86th Scientific Sessions. The triple-agonist delivered 28.3% average weight loss over 80 weeks plus large cuts in knee arthritis pain and sleep apnea severity, positioning it as the successor to Zepbound. The readout lands the same week all three major U.S. pharmacy benefit managers finally cleared Lilly's obesity portfolio for coverage, tying the supply of better drugs to the demand of who can actually pay for them.
Archive
All LLY Mover Articles
Eli Lilly Hits a Record High as Retatrutide's Phase 3 Data Lands at the ADA
LLY pushed to an all-time high near $1,226, up almost 11% in 24 hours, after Eli Lilly unveiled pivotal Phase 3 results for retatrutide at the American Diabetes Association's 86th Scientific Sessions. The triple-agonist delivered 28.3% average weight loss over 80 weeks plus large cuts in knee arthritis pain and sleep apnea severity, positioning it as the successor to Zepbound. The readout lands the same week all three major U.S. pharmacy benefit managers finally cleared Lilly's obesity portfolio for coverage, tying the supply of better drugs to the demand of who can actually pay for them.
How to Trade Eli Lilly and Company (LLY) on Hyperliquid
Eli Lilly is the largest pharmaceutical company in the world by revenue, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound that generated $36.5 billion combined in 2025. LLY is now available as a HIP-3 perpetual futures contract on Hyperliquid, giving traders leveraged exposure to one of the most consequential names in biopharma without touching traditional equity markets.
Background reading selected from this asset's symbol, builder context, and archived catalyst coverage.
HIP-3 Explained: Builder-Deployed Perps on Hyperliquid
HIP-3 lets anyone deploy a perpetual futures market on Hyperliquid — no approval, no gatekeepers. Builder mechanics, fees, and live markets.
Funding Rates Explained: A Trader's Guide (2026)
Funding rates decide if you pay or earn holding a perp position. How Hyperliquid's hourly funding works, reading rate signals, and cash-and-carry arbitrage.